A Critical Review on Emerging Trends in Dry Powder Inhaler Formulation for the Treatment of Pulmonary Aspergillosis
| Autor: | Mallikarjuna Rao Pichika, Zhi Guang Tan, Teerapol Srichana, Manisha Pandey, Hira Choudhury, Shen Nam Cheng, Bapi Gorain |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Antifungal
medicine.medical_specialty medicine.drug_class pulmonary delivery lcsh:RS1-441 Pharmaceutical Science nebulizer 02 engineering and technology Review 030226 pharmacology & pharmacy lcsh:Pharmacy and materia medica 03 medical and health sciences 0302 clinical medicine pulmonary aspergillosis Medicine Intensive care medicine nanotechnology nanocarriers business.industry dry powder inhalers 021001 nanoscience & nanotechnology Dry-powder inhaler Nebulizer Pulmonary aspergillosis Targeted drug delivery Dry powder antifungal agents Nanocarriers 0210 nano-technology business |
| Zdroj: | Pharmaceutics Pharmaceutics, Vol 12, Iss 1161, p 1161 (2020) |
| ISSN: | 1999-4923 |
| Popis: | Pulmonary aspergillosis (PA), a pulmonary fungal infection caused by Aspergillus spp., is a concern for immunocompromised populations. Despite substantial research efforts, conventional treatments of PA using antifungal agents are associated with limitations such as excessive systemic exposure, serious side effects and limited availability of the therapeutics in the lungs for an adequate duration. To overcome the limitations associated with the conventional regimens, pulmonary delivery of antifungal agents has become a focal point of research because of the superiority of local and targeted drug delivery. Dry powder inhalers and nebulized formulations of antifungal agents have been developed and evaluated for their capability to effectively deliver antifungal agents to the lungs. Moreover, progress in nanotechnology and the utilization of nanocarriers in the development of pulmonary delivery formulations has allowed further augmentation of treatment capability and efficiency. Thus, the following review provides an insight into the advantages and therapeutic potential of the utilization of nanocarriers in pulmonary delivery of antifungal agents for the treatment of PA. In addition, discussions on formulation aspects and safety concerns together with the clinical and regulatory aspects of the formulations are presented, which suggest the possibility and desirability of utilization of nanocarriers in the treatment of PA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |